Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma

被引：2
作者：
Yan, Fengting [1 ,2 ]
Gopal, Ajay K. [1 ,2 ]
Graf, Solomon A. [1 ,2 ,3 ]
机构：
[1] Univ Washington, Dept Med, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA
[3] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA
来源：
PHARMACEUTICALS | 2017年 / 10卷 / 01期
关键词：
stem cell transplantation; mantle cell lymphoma; maintenance therapy; MINIMAL RESIDUAL DISEASE; PROGRESSION-FREE SURVIVAL; PROTEASOME INHIBITOR BORTEZOMIB; PROSPECTIVE RANDOMIZED-TRIAL; CHRONIC LYMPHOCYTIC-LEUKEMIA; COOPERATIVE-ONCOLOGY-GROUP; KAPPA-B ACTIVATION; HIGH-DOSE THERAPY; PHASE-II; RITUXIMAB MAINTENANCE;
D O I：
10.3390/ph10010028
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving toward the incorporation of novel and biologically targeted pharmaceuticals with improved disease activity and gentler toxicity profiles compared with conventional chemotherapeutics. Upfront intensive treatment of MCL includes autologous stem cell transplantation (SCT) consolidation aimed at deepening and lengthening disease remission, but subsequent relapse occurs. Maintenance therapy after autologous SCT in patients with MCL in remission features lower-intensity treatments given over extended periods to improve disease outcomes. Targeted drugs are a natural fit for this space, and are the focus of considerable clinical investigation. This review summarizes recent advances in the field and their potential impact on treatment practices for MCL.
引用
收藏
页数：11
相关论文
共 58 条
[1]   Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma [J].
Andersen, Niels S. ;
Pedersen, Lone B. ;
Laurell, Anna ;
Elonen, Erkki ;
Kolstad, Arne ;
Boesen, Anne Marie ;
Pedersen, Lars M. ;
Lauritzsen, Grete F. ;
Ekanger, Roald ;
Nilsson-Ehle, Herman ;
Nordstrom, Marie ;
Freden, Susanne ;
Jerkeman, Mats ;
Eriksson, Mikael ;
Vaart, Jaan ;
Malmer, Beatrice ;
Geisler, Christian H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4365-4370
[2]   Primary treatment with autologous stem cell transplantation in mantle cell lymphoma:: outcome related to remission pretransplant [J].
Andersen, NS ;
Pedersen, L ;
Elonen, E ;
Johnson, A ;
Kolstad, A ;
Franssila, K ;
Langholm, R ;
Ralfkiær, E ;
Åkerman, M ;
Eriksson, M ;
Kuittinen, O ;
Geisler, CH .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 71 (02) :73-80
[3]  
[Anonymous], BLOOD
[4]  
[Anonymous], HAEMATOLOGICA
[5]   Bortezomib-induced peripheral neurotoxicity: an update [J].
Argyriou, Andreas A. ;
Cavaletti, Guido ;
Bruna, Jordi ;
Kyritsis, Athanasios P. ;
Kalofonos, Haralabos P. .
ARCHIVES OF TOXICOLOGY, 2014, 88 (09) :1669-1679
[6]   Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma [J].
Barth, Matthew J. ;
Mavis, Cory ;
Czuczman, Myron S. ;
Hernandez-Ilizaliturri, Francisco J. .
CLINICAL CANCER RESEARCH, 2015, 21 (19) :4391-4397
[7]   Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma:: a prospective, multicenter phase II study [J].
Brugger, W ;
Hirsch, J ;
Grünebach, F ;
Repp, R ;
Brossart, P ;
Vogel, W ;
Kopp, HG ;
Manz, MG ;
Bitzer, M ;
Schlimok, G ;
Kaufmann, M ;
Ganser, A ;
Fehnle, K ;
Gramatzki, M ;
Kanzl, L .
ANNALS OF ONCOLOGY, 2004, 15 (11) :1691-1698
[8]   High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma [J].
Cassaday, Ryan D. ;
Stevenson, Philip A. ;
Gooley, Theodore A. ;
Chauncey, Thomas R. ;
Pagel, John M. ;
Rajendran, Joseph ;
Till, Brian G. ;
Philip, Mary ;
Orozco, Johnnie J. ;
Bensinger, William I. ;
Holmberg, Leona A. ;
Shustov, Andrei R. ;
Green, Damian J. ;
Smith, Stephen D. ;
Libby, Edward N. ;
Maloney, David G. ;
Press, Oliver W. ;
Gopal, Ajay K. .
BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (05) :788-797
[9]   Incidence of Hypogammaglobulinemia in Patients Receiving Rituximab and the Use of Intravenous Immunoglobulin for Recurrent Infections [J].
Casulo, Carla ;
Maragulia, Jocelyn ;
Zelenetz, Andrew D. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (02) :106-111
[10]   Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405) [J].
Chang, Julie E. ;
Li, Hailun ;
Smith, Mitchell R. ;
Gascoyne, Randy D. ;
Paietta, Elisabeth M. ;
Yang, David T. ;
Advani, Ranjana H. ;
Horning, Sandra J. ;
Kahl, Brad S. .
BLOOD, 2014, 123 (11) :1665-1673
123456